Rocket One

Rocket One is a private biotechnology company focused on the development of next-generation adeno-associated virus (AAV) gene therapies for cardiovascular diseases. Established by the leadership team of Rocket Pharmaceuticals, the company serves as an innovation engine for early-stage genetic medicines targeting heart failure. Rocket One operates under a strategic agreement with Rocket Pharmaceuticals, which maintains an exclusive option to acquire the company and its assets. The company's research leverages advanced AAV vector technology to address genetic drivers of cardiac dysfunction that are not currently covered by the public entity's core pipeline. Rocket One is headquartered in New York and is backed by prominent life science investors including RTW Investments. The company aims to translate cutting-edge molecular biology into transformative treatments for patients with limited therapeutic options.